Lecanemab Gains FDA Approval for Early Alzheimer Disease

被引：59
作者：
Larkin, Howard D. D.
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2023年 / 329卷 / 05期
关键词：
D O I：
10.1001/jama.2022.24490
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：363 / 363
页数：1
相关论文
共 50 条
[31]   Horizon Medical gains FDA approval for catheter [J].
Anon .
Urethanes Technology, 2002, 19 (01)
[32]   Food and Drug Administration Accelerated Approval of Lecanemab for Early Alzheimer's Disease-Hope, Reality, and the Unknown Going Forward [J].
O'Malley, Patricia Anne .
CLINICAL NURSE SPECIALIST, 2023, 37 (03) :111-113
[33]   EFFICACY OF LECANEMAB IN PATIENTS WITH EARLY ALZHEIMER DISEASE: A SYSTEMATIC REVIEW AND METAANALYSIS [J].
Singh, B. ;
Kaur, G. ;
Attri, S. ;
Sharma, A. .
VALUE IN HEALTH, 2023, 26 (12) :S44-S44
[34]   Treatment of Alzheimer's disease with lecanemab [J].
Peters, O. ;
Nitschmann, S. .
INNERE MEDIZIN, 2023, 64 (04) :406-408
[35]   Lecanemab: First Approval [J].
Hoy, Sheridan M. .
DRUGS, 2023, 83 (04) :359-365
[36]   Lecanemab (Leqembi) for Alzheimer's Disease [J].
不详 .
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1669) :17-18
[37]   FDA Approval of Aduhelm Paves a New Path for Alzheimer's Disease [J].
Tanzi, Rudolph E. ;
Rose, Joseph. P. ;
Kennedy, F. .
ACS CHEMICAL NEUROSCIENCE, 2021, 12 (15) :2714-2715
[38]   Agents at the Peak of US FDA Approval for the Treatment of Alzheimer's Disease [J].
Alam, Jahngeer ;
Kalash, Anushka ;
Hassan, Md Imtaiyaz ;
Rahman, Syed Ziaur .
NEUROLOGICAL RESEARCH, 2024, 46 (04) :318-325
[39]   Rivastigmine transdermal system receives FDA approval for Alzheimer's disease [J].
Ralat, Jose .
CNS SPECTRUMS, 2007, 12 (08) :581-582
[40]   FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm [J].
Asher Mullard .
Nature Reviews Drug Discovery, 2021, 20 :496-496
12345